Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 3/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13753590 | 0.83 | MITF (0.55) | MITFIMPDH2KLK7KDM4EALDH1A1 | |
| SCHEMBL353259 | 0.83 | MITF (0.41) | MITFPLK1KLK7NPC1RAB9A | |
| SCHEMBL13753380 | 0.80 | NPC1 (0.53) | MITFIMPDH2NPC1KDM4EALDH1A1 | |
| SCHEMBL13753329 | 0.80 | MITF (0.56) | MITFIMPDH2ALDH1A1HPGDTSHR | |
| SCHEMBL16473869 | 0.79 | MITF (0.55) | MITFIMPDH2ALDH1A1HPGDTSHR | |
| SCHEMBL12988195 | 0.78 | MITF (0.49) | MITFEPHX2NR1H4IMPDH2NPC1 | |
| SCHEMBL3225051 | 0.78 | MITF (0.53) | MITFNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL13753493 | 0.78 | MITF (0.50) | MITFIMPDH2NPC1KDM4EALDH1A1 | |
| SCHEMBL3229079 | 0.77 | HTT (0.55) | MITFNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL12321783 | 0.76 | MITF (0.47) | MITFEPHX2NR1H4IMPDH2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865703-B2 | Pyridyltriazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20130225562-A1 | PYRIDYLTRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | MITF 610/4885EPHX2 2830/4885NR1H4 329/4885 |
| US-20130225562-A1 | PYRIDYLTRIAZOLES | CCNT1, CCNT2, MKI67 | MITF 787/4885EPHX2 3939/4885NR1H4 1010/4885 |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | MITF 1652/4885EPHX2 2299/4885NR1H4 109/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | MITF 1652/4885EPHX2 2299/4885NR1H4 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.